However, alectinib's activity as neoadjuvant therapy in resectable ALK-positive NSCLC has yet to be investigated despite promising efficacy and tolerability in treating advanced ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.